| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Melanie D Sweeney | Q67237677 |
| P2093 | author name string | Berislav V Zlokovic | |
| Abhay P Sagare | |||
| P2860 | cites work | Analysis of matrix metallo-proteases and the plasminogen system in mild cognitive impairment and Alzheimer's disease cerebrospinal fluid. | Q50659576 |
| Prevalence of cortical superficial siderosis in a memory clinic population. | Q50692489 | ||
| Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology. | Q50742360 | ||
| Environmental enrichment counteracts Alzheimer's neurovascular dysfunction in TgCRND8 mice. | Q51794142 | ||
| Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. | Q51944474 | ||
| Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type. | Q52033145 | ||
| Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. | Q53213249 | ||
| Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. | Q53270013 | ||
| Decline of immune responsiveness: a pathogenetic factor in Alzheimer's disease? | Q53270679 | ||
| Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease. | Q53301872 | ||
| Plasmin system of Alzheimer's disease patients: CSF analysis. | Q53327026 | ||
| Small cerebral vessel disease in familial amyloid and non-amyloid angiopathies: FAD-PS-1 (P117L) mutation and CADASIL. Immunohistochemical and ultrastructural studies. | Q53390780 | ||
| Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease. | Q53440614 | ||
| Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic mice | Q57160383 | ||
| Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis | Q57691308 | ||
| Chemokines in CSF of Alzheimer's disease patients | Q59387647 | ||
| Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia | Q72303142 | ||
| Distribution of Glut1 glucose transporters in different brain structures compared to glucose utilization and capillary density of adult rat brains | Q73089287 | ||
| Altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease | Q73114317 | ||
| Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD | Q73816529 | ||
| Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia | Q77530408 | ||
| Neurodegeneration and the neurovascular unit | Q82769596 | ||
| Biomarkers for neurology: Guides and lines | Q87644229 | ||
| Evidence for a lactate transport system in the sarcolemmal membrane of the perfused rabbit heart: kinetics of unidirectional influx, carrier specificity and effects of glucagon | Q93610981 | ||
| Current Insights into Molecular Mechanisms of Alzheimer Disease and Their Implications for Therapeutic Approaches | Q22241945 | ||
| Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease | Q22251067 | ||
| Reduction in DHA transport to the brain of mice expressing human APOE4 compared to APOE2 | Q24314295 | ||
| Pericytes Control Key Neurovascular Functions and Neuronal Phenotype in the Adult Brain and during Brain Aging | Q24600644 | ||
| Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease | Q24612662 | ||
| Pericytes are required for blood-brain barrier integrity during embryogenesis | Q24627396 | ||
| Biomarkers of Alzheimer's disease | Q24650667 | ||
| Biological markers of Alzheimer's disease | Q26823847 | ||
| The pericyte: a forgotten cell type with important implications for Alzheimer's disease? | Q26852369 | ||
| Alzheimer's disease: new data highlight nonneuronal cell types and the necessity for presymptomatic prevention strategies | Q26852851 | ||
| The pathobiology of vascular dementia | Q27006033 | ||
| Innate immunity in Alzheimer's disease: a complex affair | Q27006944 | ||
| Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease | Q27008456 | ||
| Cerebral microinfarcts: the invisible lesions | Q27026027 | ||
| The genetics of Alzheimer disease | Q27026166 | ||
| Apolipoprotein A-I: insights from redox proteomics for its role in neurodegeneration | Q27026686 | ||
| Enhancing dentate gyrus function with dietary flavanols improves cognition in older adults. | Q27312746 | ||
| Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ε4 allele | Q27331411 | ||
| Crystal structure of the human glucose transporter GLUT1 | Q27690274 | ||
| Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid | Q28115048 | ||
| A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease | Q28261647 | ||
| Mfsd2a is critical for the formation and function of the blood-brain barrier | Q28507996 | ||
| Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease | Q28586383 | ||
| Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis | Q28740917 | ||
| Angiogenesis in health and disease | Q29614541 | ||
| Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease | Q29614879 | ||
| Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders | Q29615839 | ||
| Pericytes regulate the blood-brain barrier | Q29615840 | ||
| The blood-brain barrier in health and chronic neurodegenerative disorders | Q29616411 | ||
| Neurovascular regulation in the normal brain and in Alzheimer's disease | Q29619659 | ||
| LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-β. | Q29976920 | ||
| Capillary pericytes regulate cerebral blood flow in health and disease | Q30575458 | ||
| A novel Aβ-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice | Q30579707 | ||
| Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease | Q36229619 | ||
| Blood-spinal cord barrier pericyte reductions contribute to increased capillary permeability | Q36296333 | ||
| Cerebral blood flow in Alzheimer's disease | Q36349775 | ||
| Studies on the first described Alzheimer's disease amyloid beta mutant, the Dutch variant | Q36568154 | ||
| Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease. | Q36593210 | ||
| Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis | Q36610341 | ||
| Innate immunity receptor CD36 promotes cerebral amyloid angiopathy | Q36637524 | ||
| Deficiency in mural vascular cells coincides with blood-brain barrier disruption in Alzheimer's disease | Q36773984 | ||
| Hypertension and cerebrovascular dysfunction | Q36777769 | ||
| Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B | Q37019356 | ||
| Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later | Q37035638 | ||
| The APOE ɛ4/ɛ4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer's disease patients | Q37073413 | ||
| Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease | Q37098909 | ||
| Quantitative measurement of blood-brain barrier permeability in human using dynamic contrast-enhanced MRI with fast T1 mapping | Q37108898 | ||
| Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. | Q37181246 | ||
| Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism | Q37189385 | ||
| Effectiveness of regional DTI measures in distinguishing Alzheimer's disease, MCI, and normal aging | Q37220884 | ||
| Blood pressure decrease correlates with tau pathology and memory decline in hypertensive elderly | Q37237593 | ||
| Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer disease | Q37297066 | ||
| S100beta induction of the proinflammatory cytokine interleukin-6 in neurons | Q37332541 | ||
| Pulse pressure is associated with Alzheimer biomarkers in cognitively normal older adults | Q37372458 | ||
| Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre | Q37380546 | ||
| Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. | Q37398713 | ||
| Abnormal blood-brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI | Q37414011 | ||
| Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease | Q37480839 | ||
| The association between midlife cardiorespiratory fitness levels and later-life dementia: a cohort study | Q37588769 | ||
| Pericyte loss influences Alzheimer-like neurodegeneration in mice. | Q37623577 | ||
| Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice | Q37659809 | ||
| Vascular signaling abnormalities in Alzheimer disease | Q37942551 | ||
| Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative | Q37952021 | ||
| Injury and repair in the neurovascular unit | Q38014161 | ||
| Does vascular pathology contribute to Alzheimer changes? | Q38033859 | ||
| Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes. | Q38125769 | ||
| Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study | Q38152257 | ||
| Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide™. | Q48392292 | ||
| Clinical and neuropathological findings in a patient with familial Alzheimer disease showing a mutation in the PSEN1 gene | Q48413505 | ||
| The vascular factor in Alzheimer's disease: a study in Golgi technique and electron microscopy | Q48420632 | ||
| Permeability of the blood-cerebrospinal fluid and blood-brain barriers to thyrotropin-releasing hormone | Q48427709 | ||
| Measurement of brain perfusion, blood volume, and blood-brain barrier permeability, using dynamic contrast-enhanced T(1)-weighted MRI at 3 tesla | Q48450292 | ||
| Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease | Q48453732 | ||
| Blood-brain barrier permeability to leucine-enkephalin, D-alanine2-D-leucine5-enkephalin and their N-terminal amino acid (tyrosine). | Q48479577 | ||
| A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia | Q48480350 | ||
| Reduced cerebrovascular reactivity in young adults carrying the APOE ε4 allele | Q48583004 | ||
| The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative | Q48588754 | ||
| GLUT-1 expression in the cerebra of patients with Alzheimer's disease | Q48589517 | ||
| Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier | Q48597699 | ||
| CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease | Q48605528 | ||
| Increased permeability of the blood-brain barrier and Alzheimer's disease-like alterations in slit-2 transgenic mice | Q48609716 | ||
| Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients | Q48684554 | ||
| Neuron-specific enolase, S-100 protein, myelin basic protein and lactate in CSF in dementia | Q48721686 | ||
| Blood-brain barrier permeability in Alzheimer's disease: a case-control MRI study | Q48750738 | ||
| Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease | Q48771318 | ||
| Diminished glucose transport in Alzheimer's disease: dynamic PET studies | Q48783668 | ||
| Spatial correlations between beta-amyloid (Abeta) deposits and blood vessels in familial Alzheimer's disease. | Q48787758 | ||
| Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study | Q48874950 | ||
| Pericapillary haem-rich deposits: evidence for microhaemorrhages in aging human cerebral cortex | Q48883966 | ||
| Cerebrospinal fluid neuron-specific enolase: a further marker of Alzheimer's disease? | Q49020317 | ||
| Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica | Q49061961 | ||
| Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET. | Q49145622 | ||
| Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience | Q30983673 | ||
| Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease | Q33239536 | ||
| Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system | Q33262322 | ||
| Age-related vascular pathology in transgenic mice expressing presenilin 1-associated familial Alzheimer's disease mutations | Q33556372 | ||
| Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease | Q33571894 | ||
| Multimodal techniques for diagnosis and prognosis of Alzheimer's disease | Q33607535 | ||
| Central nervous system pericytes in health and disease | Q33609398 | ||
| Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown | Q33717021 | ||
| Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. | Q33717326 | ||
| Myelin injury and degraded myelin vesicles in Alzheimer's disease | Q33791342 | ||
| Biomarkers in Alzheimer's disease: past, present and future | Q33791646 | ||
| Human cerebrospinal fluid fatty acid levels differ between supernatant fluid and brain-derived nanoparticle fractions, and are altered in Alzheimer's disease | Q33793583 | ||
| APOE epsilon4 genotype and longitudinal changes in cerebral blood flow in normal aging | Q33796980 | ||
| Cerebrospinal fluid markers of pathogenetic processes in vascular dementia, with special reference to the subcortical subtype | Q33803161 | ||
| Pinocembrin attenuates blood-brain barrier injury induced by global cerebral ischemia-reperfusion in rats. | Q33855023 | ||
| Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment | Q33894316 | ||
| Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-β is an early biomarker for mild cognitive impairment preceding Alzheimer's disease | Q33895840 | ||
| Clinical predictors of severe cerebral amyloid angiopathy and influence of APOE genotype in persons with pathologically verified Alzheimer disease | Q33911295 | ||
| ADAM10 missense mutations potentiate β-amyloid accumulation by impairing prodomain chaperone function | Q33926960 | ||
| Blood-brain barrier: a dual life of MFSD2A? | Q33967070 | ||
| Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association | Q33967781 | ||
| The future of blood-based biomarkers for Alzheimer's disease | Q34026317 | ||
| New insights into the dementia epidemic | Q34036155 | ||
| Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow | Q34042902 | ||
| Transport of leucine-enkephalin across the blood-brain barrier in the perfused guinea pig brain | Q34050246 | ||
| Cerebrospinal fluid and plasma biomarkers in Alzheimer disease | Q34098866 | ||
| Recommendations of the Alzheimer's disease-related dementias conference | Q34135726 | ||
| Effects of a disrupted blood-brain barrier on cholesterol homeostasis in the brain. | Q34141162 | ||
| Cerebral microvascular pathology in aging and Alzheimer's disease | Q34224715 | ||
| Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview | Q34277859 | ||
| Developing novel blood-based biomarkers for Alzheimer's disease | Q34394080 | ||
| Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice | Q34402693 | ||
| Diffusion tensor imaging of white matter degeneration in Alzheimer's disease and mild cognitive impairment | Q34407612 | ||
| Alzheimer's disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. | Q34411401 | ||
| Glial influence on the blood brain barrier. | Q38152380 | ||
| Adjusting the compass: new insights into the role of angiogenesis in Alzheimer's disease | Q38172335 | ||
| Alzheimer's disease genetics: from the bench to the clinic | Q38225911 | ||
| Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders | Q39140817 | ||
| Preventing Alzheimer's disease | Q39549596 | ||
| Inhibition of angiogenesis by Abeta peptides | Q40526893 | ||
| LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. | Q40528558 | ||
| Cerebrovascular permeability to peptides: manipulations of transport systems at the blood-brain barrier | Q40960259 | ||
| White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors | Q41184976 | ||
| Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors | Q41233432 | ||
| The neurovascular unit in health and disease: introduction | Q41884816 | ||
| Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity | Q42272536 | ||
| Glut1/SLC2A1 is crucial for the development of the blood-brain barrier in vivo | Q42684794 | ||
| Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms | Q43102272 | ||
| apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain | Q43243545 | ||
| Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition | Q43275099 | ||
| Increased iron levels and decreased tissue integrity in hippocampus of Alzheimer's disease detected in vivo with magnetic resonance imaging | Q43509556 | ||
| 2014 Alzheimer's disease facts and figures | Q43520458 | ||
| A derivative of myelin-associated glycoprotein in cerebrospinal fluid of normal subjects and patients with neurological disease | Q43773588 | ||
| Increased levels of CSF phosphorylated tau in apolipoprotein E epsilon4 carriers with mild cognitive impairment | Q43859052 | ||
| Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein | Q43889096 | ||
| CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects | Q44115118 | ||
| Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. | Q44315236 | ||
| RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain | Q44479225 | ||
| Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele | Q44559400 | ||
| Glucose transporter plasticity during memory processing. | Q45181863 | ||
| Substitution at codon 22 reduces clearance of Alzheimer's amyloid-beta peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood | Q46087723 | ||
| Plastic changes in the astrocyte GLUT1 glucose transporter and beta-tubulin microtubule protein following voluntary exercise in mice | Q46302210 | ||
| Vascular volume and blood-brain barrier permeability measured by dynamic contrast enhanced MRI in hippocampus and cerebellum of patients with MCI and normal controls | Q46305128 | ||
| Research priority setting: a summary of the 2012 NINDS Stroke Planning Meeting Report | Q46509113 | ||
| Multiple microbleeds are related to cerebral network disruptions in patients with early Alzheimer's disease | Q46839271 | ||
| Age-related alteration in cerebral blood flow and energy failure is correlated with cognitive impairment in the senescence-accelerated prone mouse strain 8 (SAMP8). | Q48093325 | ||
| DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial | Q48117600 | ||
| Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. | Q48126715 | ||
| Immunolabelling of hippocampal microvessel glucose transporter protein is reduced in Alzheimer's disease | Q48224335 | ||
| Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia | Q48246691 | ||
| Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease | Q48253639 | ||
| Soluble adhesion molecules and angiotensin-converting enzyme in dementia | Q48290054 | ||
| Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE) in Alzheimer's disease | Q48310556 | ||
| Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. | Q48380741 | ||
| Pinocembrin protects against β-amyloid-induced toxicity in neurons through inhibiting receptor for advanced glycation end products (RAGE)-independent signaling pathways and regulating mitochondrion-mediated apoptosis | Q34417983 | ||
| Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography | Q34435040 | ||
| The role of activated astrocytes and of the neurotrophic cytokine S100B in the pathogenesis of Alzheimer's disease | Q34469528 | ||
| Microvascular injury and blood-brain barrier leakage in Alzheimer's disease | Q34539460 | ||
| Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases. | Q34549555 | ||
| Microinfarct pathology, dementia, and cognitive systems | Q34590151 | ||
| Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease | Q34606557 | ||
| 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects | Q34637899 | ||
| Imaging cerebral amyloid angiopathy with susceptibility-weighted imaging. | Q34653498 | ||
| Alzheimer disease and cerebrovascular pathology: an update | Q34732659 | ||
| Activated protein C: potential therapy for severe sepsis, thrombosis, and stroke | Q34747354 | ||
| Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease | Q34960461 | ||
| Human apolipoprotein E ɛ4 expression impairs cerebral vascularization and blood-brain barrier function in mice | Q34976193 | ||
| Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer's disease are centered on vessel walls | Q35085065 | ||
| Blood-brain barrier breakdown in the aging human hippocampus | Q35151019 | ||
| APOE and Alzheimer disease: a major gene with semi-dominant inheritance | Q35181990 | ||
| Reduction of amyloid angiopathy and Abeta plaque burden after enriched housing in TgCRND8 mice: involvement of multiple pathways | Q35222000 | ||
| Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly | Q35231622 | ||
| Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer's disease | Q35232491 | ||
| Human apoE isoforms differentially regulate brain amyloid-β peptide clearance | Q35334161 | ||
| Intrathecal inflammation precedes development of Alzheimer's disease | Q35476365 | ||
| Vascular plasticity and cognition during normal aging and dementia | Q35598028 | ||
| Fibrinogen-induced increased pial venular permeability in mice | Q35667573 | ||
| Biomarkers for predicting cognitive decline in those with normal cognition | Q35714382 | ||
| Oxidative stress signalling in Alzheimer's disease | Q35725966 | ||
| A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain | Q35841946 | ||
| Neurovascular mechanisms of Alzheimer's neurodegeneration | Q36088588 | ||
| Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents | Q36110188 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International | Q42553662 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| dementia | Q83030 | ||
| brain | Q1073 | ||
| Alzheimer's disease | Q11081 | ||
| cerebrospinal fluid | Q54196 | ||
| nervous system | Q9404 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1055-1068 | |
| P577 | publication date | 2015-04-22 | |
| 2015-07-01 | |||
| P1433 | published in | Journal of Cerebral Blood Flow & Metabolism | Q14663525 |
| P1476 | title | Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease | |
| P478 | volume | 35 |
| Q27301267 | Alzheimer's disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression |
| Q46165463 | Alzheimer's disease: A matter of blood-brain barrier dysfunction? |
| Q57023036 | Blood-Brain Barrier: From Physiology to Disease and Back |
| Q47707801 | Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders |
| Q91046010 | Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction |
| Q31066988 | Brain imaging of neurovascular dysfunction in Alzheimer's disease |
| Q39313671 | Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease |
| Q47809090 | Combustion-Derived Nanoparticles in Key Brain Target Cells and Organelles in Young Urbanites: Culprit Hidden in Plain Sight in Alzheimer's Disease Development |
| Q36306827 | Establishment and Dysfunction of the Blood-Brain Barrier |
| Q39131972 | Folate nutrition and blood-brain barrier dysfunction. |
| Q60912208 | Functional and morphological changes of the retinal vessels in Alzheimer's disease and mild cognitive impairment |
| Q46403676 | Glycosylation of dentin matrix protein 1 is a novel key element for astrocyte maturation and BBB integrity |
| Q37104293 | Hyperhomocysteinemia exacerbates Alzheimer's disease pathology by way of the β-amyloid fibrinogen interaction |
| Q37346081 | Identifying biomarkers of dementia prevalent among amnestic mild cognitively impaired ethnic female patients |
| Q37048785 | Interactions between Flow Oscillations and Biochemical Parameters in the Cerebrospinal Fluid |
| Q92382299 | Latest advances in cerebrospinal fluid and blood biomarkers of Alzheimer's disease |
| Q90220710 | Nanomaterial-based blood-brain-barrier (BBB) crossing strategies |
| Q97418952 | Neuronal regulation of the blood-brain barrier and neurovascular coupling |
| Q36767796 | Neurovascular dysfunction and neurodegeneration in dementia and Alzheimer's disease |
| Q38798483 | Oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling |
| Q90297013 | Oxidative Stress: A Major Player in Cerebrovascular Alterations Associated to Neurodegenerative Events |
| Q89519028 | PRDM16 orchestrates angiogenesis via neural differentiation in the developing brain |
| Q38844788 | Pericytes of the neurovascular unit: key functions and signaling pathways. |
| Q36853502 | Recent Developments in Understanding Brain Aging: Implications for Alzheimer's Disease and Vascular Cognitive Impairment. |
| Q35650286 | Role of membrane biophysics in Alzheimer's-related cell pathways. |
| Q38662677 | Strategies for transporting nanoparticles across the blood-brain barrier |
| Q53376342 | Strong Impact of Chronic Cerebral Hypoperfusion on Neurovascular Unit, Cerebrovascular Remodeling, and Neurovascular Trophic Coupling in Alzheimer's Disease Model Mouse. |
| Q38937398 | Systems-level thinking for nanoparticle-mediated therapeutic delivery to neurological diseases |
| Q30239749 | The blood brain barrier in Alzheimer's disease. |
| Q59784797 | The role of brain vasculature in neurodegenerative disorders |
| Q90383149 | Type 2 Diabetes Mellitus Increases The Risk of Late-Onset Alzheimer's Disease: Ultrastructural Remodeling of the Neurovascular Unit and Diabetic Gliopathy |
Search more.